Shares Up Again TodayProtectan CBLB612 Showing Effectiveness as a Stem Cell Compound
Share price heads north again today, after thestreet.com reported the news yesterday of the encouraging animal study.
Cleveland BioLabs reported that a study for Protectan CBLB612 showed blood from healthy mice treated with the drug, helped mice issued a normally lethal dose of radiation survive past the 60-day mark. The company said the experiment demonstrated effectiveness in stimulation and mobilization of stem cells.